{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.4","upperLimit":"36.9","value":"20.0"},{"groupId":"OG001","lowerLimit":"18.4","upperLimit":"67.1","value":"41.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"Positive"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.6","upperLimit":"30.4","value":"20.5"},{"groupId":"OG001","lowerLimit":"13.2","upperLimit":"40.3","value":"25.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"44"}],"units":"Participants"}],"title":"Negative"}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"61"}],"units":"Participants"}],"description":"ORR is defined as the best overall response (BOR) of a complete response (CR) or partial response (PR) divided by the number of randomized participants for each treatment group.\n\nComplete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes(whether target or non-target) must have reduction in short axis to \\< 10 mm.\n\nPartial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with histologically confirmed Squamous Cell Carcinoma of the Head and Neck (SCCHN) who are platinum naive or have recurred 6 months or more after completion of previous platinum-based chemotherapy.\n\nTreated with Nivolumab 3 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W","id":"OG000","title":"Treatment A - Platinum Eligible Subgroup"},{"description":"Participants with histologically confirmed Squamous Cell Carcinoma of the Head and Neck (SCCHN) who are platinum naive or have recurred 6 months or more after completion of previous platinum-based chemotherapy.\n\nTreated with Nivolumab 3 mg/kg Q2W + Ipilimumab-Placebo Q6W","id":"OG001","title":"Treatment B - Platinum Eligible Subgroup"}],"paramType":"NUMBER","populationDescription":"All Randomized Participants - Platinum Eligible Subgroup","reportingStatus":"POSTED","timeFrame":"From randomization to end of study. Approximately 63 Months","title":"ORR - Platinum Eligible Subgroup Based on HPV p-16 Status","type":"SECONDARY","unitOfMeasure":"percentage of participants"}